Publications by authors named "Rebecca Wrishko"

Claim this Profile
S
Sugammadex for Reversal of Neuromuscular Blockade in Neonates and Infants Less than 2 Years Old: Results from a Phase IV Randomized Clinical Trial.
Edith Mensah-Osman, Yuki Mukai, Aobo Wang, Maria Matuszczak, Vera Saldien, Rebecca Wrishko

Anesthesiology· August 2025

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
A
A population pharmacokinetic model for posaconazole intravenous solution and oral powder for suspension formulations in pediatric patients with neutropenia.
Gregory Winchell, Rik de Greef, Aziz Ouerdani, Floris Fauchet, Rebecca E Wrishko

Antimicrob Agents Chemother· April 2024

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
P
Pharmacokinetic and Exposure Response Analysis of the Double-Blind Randomized Study of Posaconazole and Voriconazole for Treatment of Invasive Aspergillosis.
Johan A Maertens, Galia Rahav, Dong-Gun Lee, Shariq Haider, Isabel Cristina Ramirez-Sanchez, Rebecca Wrishko

Clin Drug Investig· September 2023

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
P
Pharmacokinetics of intravenous daptomycin in Japanese pediatric patients: Pharmacokinetic comparisons supporting dosing recommendations in Japanese pediatric patients.
Mikio Ishii, Yuji Orito, Mari Shiomi, Rebecca E Wrishko, Hiroyuki Yoshitsugu

J Infect Chemother· June 2023

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
M
Model-Informed Dose Justifications of Posaconazole in Japanese Patients for Prophylaxis and Treatment Against Fungal Infection.
Takashi Iwasa, Camila de Almeida, Floris Fauchet, Gregory A Winchell, Rik de Greef, Rebecca Ellen Wrishko

J Clin Pharmacol· April 2023

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
P
Predicted Bezlotoxumab Exposure in Patients Who Have Received a Hematopoietic Stem Cell Transplant.
Camila de Almeida, Michael Wong, Huub Jan Kleijn, Rebecca E Wrishko

Clin Ther· April 2023

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
S
Sugammadex for reversal of neuromuscular blockade in pediatric patients: Results from a phase IV randomized study.
Tiffini Voss, Aobo Wang, Matthew DeAngelis, Marcel Speek, Vera Saldien, Rebecca Wrishko

Paediatr Anaesth· March 2022

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
P
Pharmacokinetics of Sugammadex Dosed by Actual and Ideal Body Weight in Patients With Morbid Obesity Undergoing Surgery.
Kate Mostoller, Rebecca Wrishko, Lata Maganti, W Joseph Herring, Mariëlle van Zutphen-van Geffen

Clin Transl Sci· March 2021

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
A
Assessment of Bezlotoxumab Immunogenicity.
Diana L Montgomery, Randolph P Matthews, Ka Lai Yee, Lori M Tobias, Mary Beth Dorr, Rebecca E Wrishko

Clin Pharmacol Drug Dev· April 2020

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
A
A time-to-event analysis of the exposure-response relationship for bezlotoxumab concentrations and CDI recurrence.
Ka Lai Yee, Huub Jan Kleijn, Stefan Zajic, Mary Beth Dorr, Rebecca E Wrishko

J Pharmacokinet Pharmacodyn· April 2020

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
M
Modeling and Simulation Analysis of Aprepitant Pharmacokinetics in Pediatric Patients With Postoperative or Chemotherapy-Induced Nausea and Vomiting.
Anne Chain, Rebecca Wrishko, Grygoriy Vasilinin, Samer Mouksassi

J Pediatr Pharmacol Ther· January 2020

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
T
The Bioequivalence and Effect of Food on the Pharmacokinetics of a Fixed-Dose Combination Tablet Containing Rosuvastatin and Ezetimibe in Healthy Japanese Subjects.
Chisato Nishida, Yuki Matsumoto, Katsukuni Fujimoto, Masayoshi Shirakawa, Rebecca Ellen Wrishko

Clin Transl Sci· November 2019

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
E
Effect of CYP3A Inhibition and Induction on the Pharmacokinetics of Suvorexant: Two Phase I, Open-Label, Fixed-Sequence Trials in Healthy Subjects.
Rebecca E Wrishko, Jacqueline B McCrea, Ka Lai Yee, Wen Liu, Deborah Panebianco

Clin Drug Investig· May 2019

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
C
Correction to: Effect of CYP3A Inhibition and Induction on the Pharmacokinetics of Suvorexant: Two Phase I, Open-Label, Fixed-Sequence Trials in Healthy Subjects.
Rebecca E Wrishko, Jacqueline B McCrea, Ka Lai Yee, Wen Liu, Deborah Panebianco

Clin Drug Investig· May 2019

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
P
Population Pharmacokinetics and Pharmacodynamics of Bezlotoxumab in Adults with Primary and Recurrent Infection.
Ka Lai Yee, Huub Jan Kleijn, Thomas Kerbusch, Randolph P Matthews, Mary Beth Dorr, Rebecca E Wrishko

Antimicrob Agents Chemother· February 2019

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
S
Safety, Tolerability, and Pharmacokinetics of Suvorexant: A Randomized Rising-Dose Trial in Healthy Men.
Ka Lai Yee, Jacqueline McCrea, Deborah Panebianco, Wen Liu, Nicole Lewis, Rebecca E Wrishko

Clin Drug Investig· July 2018

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
P
Pharmacokinetics of sugammadex in subjects with moderate and severe renal impairment
.
K Chris Min, Kenneth C Lasseter, Thomas C Marbury, Rebecca E Wrishko, William D Hanley

Int J Clin Pharmacol Ther· September 2017

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
O
On-the-road driving performance the morning after bedtime use of suvorexant 15 and 30 mg in healthy elderly.
Annemiek Vermeeren, Eva Vets, Eric F P M Vuurman, Anita C M Van Oers, Stefan Jongen, Rebecca Wrishko

Psychopharmacology (Berl)· September 2016

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
O
On-the-Road Driving Performance the Morning after Bedtime Use of Suvorexant 20 and 40 mg: A Study in Non-Elderly Healthy Volunteers.
Annemiek Vermeeren, Hong Sun, Eric F P M Vuurman, Stefan Jongen, Cees J Van Leeuwen, Rebecca Wrishko

Sleep· November 2015

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
R
Relationship between exposure to prasugrel active metabolite and clinical outcomes in the TRITON-TIMI 38 substudy.
Jeffrey S Riesmeyer, Daniel E Salazar, Govinda J Weerakkody, Lan Ni, Rebecca E Wrishko

J Clin Pharmacol· June 2012

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
E
Effect of age on the pharmacokinetics and pharmacodynamics of prasugrel during multiple dosing: an open-label, single-sequence, clinical trial.
David S Small, Rebecca E Wrishko, C Steven Ernest, Lan Ni, Kenneth J Winters

Drugs Aging· October 2009

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
P
Population pharmacokinetic analyses to evaluate the influence of intrinsic and extrinsic factors on exposure of prasugrel active metabolite in TRITON-TIMI 38.
Rebecca E Wrishko, C Steven Ernest, David S Small, Ying G Li, Govinda J Weerakkody

J Clin Pharmacol· August 2009

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
P
Prediction of prasugrel active metabolite concentrations from 2 downstream inactive metabolite concentrations using multilinear regression analysis.
C Steven Ernest, Michael A Heathman, Rebecca E Wrishko

J Clin Pharmacol· August 2009

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
S
Safety, efficacy, and pharmacokinetic overview of low-dose daily administration of tadalafil.
Rebecca Wrishko, Sebastian Sorsaburu, David Wong, Andrew Strawbridge, James McGill

J Sex Med· July 2009

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
P
Population pharmacokinetics and pharmacodynamics of prasugrel and clopidogrel in aspirin-treated patients with stable coronary artery disease.
C Steven Ernest, David S Small, Shashank Rohatagi, Daniel E Salazar, Lars Wallentin, Rebecca E Wrishko

J Pharmacokinet Pharmacodyn· December 2008

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis